Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) May 10, 2017 5:00pm EDT
Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team May 10, 2017 8:00am EDT
Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights May 04, 2017 4:15pm EDT
Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC) Apr 21, 2017 8:00am EDT
Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 Apr 20, 2017 4:20pm EDT
Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer Apr 03, 2017 8:00am EDT
Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS) Mar 17, 2017 12:45pm EDT
Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights Mar 09, 2017 8:00am EST
Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) Jan 03, 2017 8:00am EST
